Papillary thyroid cancer located in malignant struma ovarii with omentum metastasis: a case report and review of the literature

World Journal of Surgical Oncology

Case Report

Chang Wang¹  Guo-Nan Zhang²  Shi-Qiang Xu²  Yu Shi²  Yi Zhu³  Shi-Jun Jia⁴  Rong He⁵ 

[1]Department of Gynaecology and Obstetrics, Chengdu First People’s Hospital, Chengdu, Sichuan, China

[2]Department of Gynecological Oncology, Sichuan Cancer Hospital, No. 55, Section 4, South People’s Road, 610041, Chengdu, Sichuan, China

[3]Department of Gynecological Oncology, Sichuan Cancer Hospital, No. 55, Section 4, South People’s Road, 610041, Chengdu, Sichuan, China

[4]Department of Ultrasound, Sichuan Cancer Hospital, Chengdu, Sichuan, China

[5]Department of Pathology, Sichuan Cancer Hospital, Chengdu, Sichuan, China

[6]Department of Ultrasound, Sichuan Cancer Hospital, Chengdu, Sichuan, China

关键词: Struma ovarii;    Papillary thyroid cancer;    Metastases;   

DOI  :  10.1186/s12957-016-0776-x

 received in 2015-06-27, accepted in 2016-01-11,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe present of malignant transformation in struma ovarii is exceedingly rare. Malignant struma ovarii is usually asymptomatic and infrequently diagnosed preoperatively. Because of its rarity, there is no consensus about diagnosis and management in the literature.Case presentationA 40-year-old female presented for her obstetric examination with an incidental finding of a pelvic mass. Patient was asymptomatic at presentation. A follow-up ultrasound confirmed the presence of a 3-cm mass in the left adnexa. Patient underwent a cytoreductive surgery (hysterectomy, bilateral salpingectomy and oophorectomy, omentectomy, appendectomy, and pelvic lymphadenectomy). Histopathology revealed a malignant struma ovarii with a focus of papillary thyroid carcinoma and the omentum metastasis. The patient with stage FIGO IIIc received 6 cycles of paclitaxel/carboplatin regimen after surgery. The patient subsequently had a thyroid scan that was normal with normal thyroid function. At a follow-up of 12 months, she is alive, in good clinical condition, and disease-free.ConclusionsBecause of the rarity of these tumors and their lack of firm prognostic factors, treatment decisions should be made individually, based on pathologic and clinical parameters.

【 授权许可】

CC BY   
© Zhu et al. 2016